Rigel Q3 Revenue Rises to $80.9M on VEPPANU Launch; Net Income Falls to $13.2M
RIGL sits 76% above its 52-week low of $24.95 on elevated volume (2.2× avg).
Summary
Rigel's Q3 2026 revenue rose to $80.9M from $69.5M, including $6.6M of first VEPPANU sales, but net income fell to $13.2M from $27.9M on launch costs and the absence of last year's one-time Lilly gain. Cash and investments stand at $99.3M, which management says covers at least 12 months.
Key Events · Earnings and Guidance · RIGL
-
Q3 Revenue Grows on VEPPANU Launch
Total revenues were $80.9M versus $69.5M a year ago, with net product sales of $72.3M versus $64.1M. VEPPANU contributed $6.6M from its August 13, 2026 commercial launch through September 30.
-
Net Income Falls to $13.2M
Q3 net income was $13.2M, or $0.70 basic and $0.65 diluted per share, versus $27.9M a year ago. The prior-year quarter included a $40.0M non-cash release of the Lilly cost-share liability.
-
Cash Drops After $70M VEPPANU Upfront
Cash, equivalents and short-term investments were $99.3M at September 30, 2026 versus $155.0M at December 31, 2025, after the $70.0M upfront payment to Arvinas and Pfizer. Management states this funds at least the next 12 months.
-
Debt Refinanced Into $40M Revolver
The $60.0M MidCap term loan was repaid on May 5, 2026 and replaced with a $40.0M revolving facility; $8.0M was outstanding at a 7.7% weighted-average rate at quarter end, with no covenant violations.
Analysis · RIGL · Life Sciences
Revenue grew but profit shrank: Q3 net income fell to $13.2M from $27.9M a year ago, because the year-ago quarter carried a one-time $40.0M non-cash gain from releasing the Lilly cost-share liability, while this quarter absorbs the cost of launching VEPPANU. The launch itself is the number that matters — $6.6M of VEPPANU sales in roughly seven weeks since the August 13, 2026 commercial start, on top of TAVALISSE at $46.0M and REZLIDHIA at $9.9M, both up year over year, while GAVRETO slipped 11% to $9.8M. Cash is the constraint: $99.3M in cash and short-term investments at September 30, 2026, down from $155.0M at December 31, 2025 after the $70.0M VEPPANU upfront payment, against a $24.8M Pfizer take-or-pay supply commitment and $15.7M of contract-manufacturing obligations. Management says the balance funds at least the next 12 months, and the $100M at-the-market facility remains unused.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RIGL was trading at $44.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $853.9M. The 52-week trading range was $24.95 to $52.61. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.